Sagimet Biosciences Inc. announced positive results from a Phase 1 pharmacokinetic $(PK)$ clinical trial evaluating the combination of its oral fatty acid synthase (FASN) inhibitor, denifanstat, with the thyroid hormone receptor beta (THR-β) agonist, resmetirom. The study enrolled 40 healthy adult participants and assessed the safety, tolerability, and potential drug-drug interactions of the combination. The results indicated that the combination was generally well-tolerated, with no serious adverse events or treatment discontinuations reported. These Phase 1 results have already been presented, and Sagimet plans to advance the combination into a Phase 2 proof-of-concept efficacy trial for patients with metabolic dysfunction-associated steatohepatitis (MASH) with F4 fibrosis, expected to initiate in the second half of 2026.